This specialized case study explores Kymanox’s approach to assessing and optimizing the Quality Management System (QMS) for a specialty pharmaceutical company in alignment with 21 CFR Part 4. Out team of SMEs collaborated closely with stakeholders to implement measurable improvements across QMS gap closure, Corrective And Preventive Action (CAPA) process visibility, and regulatory compliance tracking, ensuring ongoing adherence to industry standards.
CHALLENGE
SOLUTION
RESULTS
- Conduct a gap assessment of the Client’s QMS for compliance with 21 CFR Part 4 regulations.
- Review ten (10) CAPAs and related deviations for adherence to 21 CFR Part 4 and internal procedures.
- Provide actionable findings and recommendations regarding QMS compliance and CAPA metrics.
- Performed a thorough QMS gap assessment against regulatory standards, reference current FDA guidance and requirements for combination products and specialty pharma.
- Reviewed CAPAs and deviations, assessing key compliance metrics such as on-time completion rate, number of extensions, and effectiveness check outcomes.
- Delivered a preliminary report outlining gap assessment findings and actionable recommendations for remediation and continuous improvement.
- Enaged with CAPA process ownders to clarify compliance standards and expectations.
- Continued review of additional CAPAs and deviations to provide ongoing compliance metrics and support.
- Provided a preliminary report with targeted findings and remediation recommendations, enhancing the Client’s ability to track and improve QMS compliance.
- Enabled ongoing adherence to 21 CFR Part 4 through regular CAPA metric reporting and process visibility.
- Improved tracking and visibility for CAPA closure, helping the Client maintain regulatory readiness and mitigate compliance risks.